专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010011346A1 RNAI CONSTRUCTS AND USES THEROF 审中-公开
标题翻译： RNAI构建和使用
公开(公告)号：WO2010011346A1
公开(公告)日：2010-01-28
申请号：PCT/US2009004326
申请日：2009-07-23
申请人： RXI PHARMACEUTICALS CORP , SAMARSKY DMITRY , WOOLF TOD , SALOMON WILLIAM , KAMENS JOANNE , KHVOROVA ANASTASIA , PAVCO PAMELA A
发明人： SAMARSKY DMITRY , WOOLF TOD , SALOMON WILLIAM , KAMENS JOANNE , KHVOROVA ANASTASIA , PAVCO PAMELA A
IPC分类号： A61K31/712 , A61K31/713 , C12N15/11 , C12N15/113
CPC分类号： C12N15/1137 , C12N15/111 , C12N2310/14 , C12N2310/531 , C12N2310/533 , C12N2320/51
摘要： The invention relates to improved double-stranded RNAi constructs (sometimes referred to as "solo-rxRNA") and uses thereof. The construct comprises a structure formed in some aspects of the invention by two identical single-stranded polynucleotides, with the structure having two double-stranded stem regions (each having less than 21 base pairs) and a loop or bulge having about 4 to 11 nucleotides on each strand. The construct is resistant to cleavage by Dicer or other Dicer-like RNase III enzymes and is capable of being loaded into a RISC complex to effect RNA interference. In addition, the nucleotides of the present hairpin constructs may be modified to greatly enhance functionality, such as stability and specificity.
摘要翻译：本发明涉及改进的双链RNAi构建体（有时称为“solo-rxRNA”）及其用途。该构建体包含在本发明的一些方面中由两个相同的单链多核苷酸形成的结构，该结构具有两个双链干区（每个具有少于21个碱基对）和具有约4至11个核苷酸的环或凸起在每条链上。该构建体对Dicer或其他类似切酶的RNA酶III酶的切割具有抗性，并且能够加载到RISC复合物中以实现RNA干扰。另外，可以修饰本发明构建体的核苷酸以大大增强功能性，例如稳定性和特异性。

2. 发明专利

AU2009293658A1 Reduced size self-delivering RNAi compounds 未知
公开(公告)号：AU2009293658A1
公开(公告)日：2010-03-25
申请号：AU2009293658
申请日：2009-09-22
申请人： CARDIA JAMES , KAMENS JOANNE , KHVOROVA ANASTASIA , RXI PHARMACEUTICALS CORP , SALOMON WILLIAM , SAMARSKY DMITRY , WOOLF TOD M
发明人： KHVOROVA ANASTASIA , SALOMON WILLIAM , KAMENS JOANNE , SAMARSKY DMITRY , WOOLF TOD M , CARDIA JAMES
IPC分类号： C12N15/113 , A61K31/713
摘要： The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.

3. 发明申请

WO2009102427A3 MODIFIED RNAI POLYNUCLEOTIDES AND USES THEREOF 审中-公开
标题翻译：修饰的RNAi多核苷酸及其用途
公开(公告)号：WO2009102427A3
公开(公告)日：2009-12-23
申请号：PCT/US2009000852
申请日：2009-02-11
申请人： RXI PHARMACEUTICALS CORP , PAVCO PAMELA A , KAMENS JOANNE , WOOLF TOD M , SALOMON WILLIAM , KHVOROVA ANASTASIA
发明人： PAVCO PAMELA A , KAMENS JOANNE , WOOLF TOD M , SALOMON WILLIAM , KHVOROVA ANASTASIA
IPC分类号： A61K31/713 , C07H21/02 , C12N15/113
CPC分类号： C12N15/111 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2320/51 , C12N2320/53 , C12N2310/3521
摘要： The invention relates to improved RNAi constructs and uses thereof. The construct has a double stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the sense strand may be modified (e.g., one or both ends of the sense strand is/are modified by four 2'-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2'-O-methyl group at the 2nd 5'-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoids the interferon response and sequence- independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.
摘要翻译：本发明涉及改进的RNAi构建体及其用途。构建体具有19-49个核苷酸的双链区，优选25,26或27个核苷酸，并且优选平末端。该构建体具有选择性最小修饰以赋予生物活性，毒性，稳定性和靶基因特异性的最佳平衡。例如，有义链可以被修饰（例如，有义链的一个或两个末端被4个2'-O-甲基修饰），使得构建体不被切酶或其他RNA酶III切割，以及反义链的整个长度被加载到RISC中。另外，反义链也可以通过第2个5'-末端核苷酸上的2'-O-甲基修饰，以大大减少脱靶沉默。本发明的构建体在很大程度上避免了哺乳动物细胞中的干扰素应答和序列非依赖性细胞凋亡，表现出更好的血清稳定性和增强的靶特异性。

4. 发明申请

WO2010033248A3 NEUTRAL NANOTRANSPORTERS 审中-公开
标题翻译：中性纳米转运体
公开(公告)号：WO2010033248A3
公开(公告)日：2010-06-17
申请号：PCT/US2009005251
申请日：2009-09-22
申请人： RXI PHARMACEUTICALS CORP , KHVOROVA ANASTASIA , SALOMON WILLIAM , KAMENS JOANNE , SAMARSKY DMITRY , WOOLF TOD M , MILLER MICHELLE , BULOCK KAREN G
发明人： KHVOROVA ANASTASIA , SALOMON WILLIAM , KAMENS JOANNE , SAMARSKY DMITRY , WOOLF TOD M , MILLER MICHELLE , BULOCK KAREN G
IPC分类号： C12N15/113 , A61K31/7088
CPC分类号： C12N15/1136 , C12N15/111 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3341 , C12N2310/3515 , C12N2310/3519 , C12N2320/32 , C12N2320/51 , C12N2310/3521
摘要： Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.
摘要翻译：根据本发明提供了用于核酸递送的中性脂质制剂。中性脂质制剂包括疏水改性的多核苷酸和脂肪混合物。还提供了使用中性脂质制剂的方法。

5. 发明申请

WO2010033247A3 REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS 审中-公开
标题翻译：减少尺寸自交RNAi化合物
公开(公告)号：WO2010033247A3
公开(公告)日：2010-06-03
申请号：PCT/US2009005247
申请日：2009-09-22
申请人： RXI PHARMACEUTICALS CORP , KHVOROVA ANASTASIA , SALOMON WILLIAM , KAMENS JOANNE , SAMARSKY DMITRY , WOOLF TOD M , CARDIA JAMES
发明人： KHVOROVA ANASTASIA , SALOMON WILLIAM , KAMENS JOANNE , SAMARSKY DMITRY , WOOLF TOD M , CARDIA JAMES
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： C12N15/1136 , C12N15/111 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3341 , C12N2310/3515 , C12N2310/3519 , C12N2320/32 , C12N2320/51 , C12N2310/3521
摘要： The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
摘要翻译：本发明涉及具有最小双链区的RNAi构建体及其在基因沉默中的应用。与本发明相关的RNAi构建体包括8-14个核苷酸的双链区域和各种化学修饰，并且在基因沉默中是非常有效的。

6. 发明申请

WO2010059226A3 INHIBITION OF MAP4K4 THROUGH RNAI 审中-公开
标题翻译：通过RNAi抑制MAP4K4
公开(公告)号：WO2010059226A3
公开(公告)日：2010-07-15
申请号：PCT/US2009006211
申请日：2009-11-19
申请人： RXI PHARMACEUTICALS CORP , WOOLF TOD M , KAMENS JOANNE , KHVOROVA ANASTASIA , SALOMON WILLIAM
发明人： WOOLF TOD M , KAMENS JOANNE , KHVOROVA ANASTASIA , SALOMON WILLIAM
IPC分类号： C07H21/02 , A61K31/7088
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/321 , C12N2320/11 , C12N2320/30 , C12Y207/01037
摘要： RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e g., one or both ends of the sense strand is modified by 2'-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2'-O-methyl group at the penultimate 5'-end nucleotide to greatly reduce off- target silencing.
摘要翻译：公开了针对表达意想不到的高基因沉默活性的MAP4K4的RNAi构建体及其用途。平端构建体具有19-49个核苷酸的双链区域。该构建体具有选择性的最小修饰以赋予生物活性，毒性，稳定性和靶基因特异性的最佳平衡。例如，可以修饰链（例如，有义链的一个或两个末端被2'-O-甲基修饰），使得构建体不被Dicer或其他RNA酶III切割，反义链也可以在倒数第二个5'-末端核苷酸处被2'-O-甲基修饰，以大大减少脱靶沉默。

7. 发明申请

WO2008079361A3 CXCL13 BINDING PROTEINS 审中-公开
标题翻译： CXCL13结合蛋白
公开(公告)号：WO2008079361A3
公开(公告)日：2008-10-16
申请号：PCT/US2007026217
申请日：2007-12-21
申请人： ABBOTT LAB , KAMENS JOANNE
发明人： KAMENS JOANNE
IPC分类号： A61K39/395
CPC分类号： A61K51/1021 , A61K47/6845 , C07K16/24 , C07K2317/76 , C07K2317/92
摘要： The present invention encompasses CXCL13 binding proteins. Specifically, the invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for CXCL13 and CXCL13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting mouse CXCL13 and for inhibiting mouse CXCL13 activity, e.g., in a mammal suffering from a disorder in which CXCL13 activity is detrimental.
摘要翻译：本发明涵盖CXCL13结合蛋白。具体地，本发明涉及野生型，嵌合型，CDR移植和人源化的抗体。优选的抗体在体外和体内对CXCL13和CXCL13活性具有高亲和力。本发明的抗体可以是全长抗体或其抗原结合部分。还提供了制备方法和使用本发明抗体的方法。本发明的抗体或抗原结合部分可用于检测小鼠CXCL13和抑制小鼠CXCL13活性，例如在患有CXCL13活性有害的病症的哺乳动物中。

8. 发明专利

CA2743981A1 REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS 未知
公开(公告)号：CA2743981A1
公开(公告)日：2010-03-25
申请号：CA2743981
申请日：2009-09-22
申请人： RXI PHARMACEUTICALS CORP
发明人： KHVOROVA ANASTASIA , SALOMON WILLIAM , KAMENS JOANNE , SAMARSKY DMITRY , WOOLF TOD M , CARDIA JAMES
IPC分类号： C12N15/113 , A61K31/713
摘要： The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.

9. 发明专利

AU2011232365A1 RNA interference in dermal and fibrotic indications 未知
公开(公告)号：AU2011232365A1
公开(公告)日：2012-10-25
申请号：AU2011232365
申请日：2011-03-24
申请人： RXI PHARMACEUTICALS CORP
发明人： KHVOROVA ANASTASIA , SALOMON WILLIAM , KAMENS JOANNE , SAMARSKY DMITRY , WOOLF TOD M , PAVCO PAMELA A , LIBERTINE LYN , CARDIA JAMES
IPC分类号： A61K31/713 , C07H21/02
摘要： The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.

10. 发明专利

CA2715289A1 MODIFIED RNAI POLYNUCLEOTIDES AND USES THEREOF 未知
公开(公告)号：CA2715289A1
公开(公告)日：2009-08-20
申请号：CA2715289
申请日：2009-02-11
申请人： RXI PHARMACEUTICALS CORP
发明人： PAVCO PAMELA A , KAMENS JOANNE , WOOLF TOD M , SALOMON WILLIAM , KHVOROVA ANASTASIA
IPC分类号： A61K31/713 , C07H21/02 , C12N15/113
摘要： The invention relates to improved RNAi constructs and uses thereof. The construct has a double stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the sense strand may be modified (e.g., one or both ends of the sense strand is/are modified by four 2'-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2'-O-methyl group at the 2nd 5'-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoids the interferon response and sequence- independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式